Abstract
BackgroundRemarkable breakthroughs in immune checkpoint inhibitors (ICIs) for treating driverless target lung cancers have resulted in significant patient survival benefits. However, the efficacy of this approach in lung cancer patients...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
